New drug aims to wipe out lingering cancer DNA after standard treatment
NCT ID NCT05414032
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a drug called AZD2936 in people with high-risk head and neck cancer who still have traces of cancer DNA in their blood after completing standard treatment. The drug is designed to boost the immune system to find and destroy these remaining cancer cells. About 100 participants will be enrolled to see if the drug can clear the cancer DNA and prevent the disease from returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD2936 (an antibody that boosts the immune system to fight cancer)
- What this could lead to
- If successful, this could offer a way to eliminate remaining cancer cells after standard treatment, potentially preventing the cancer from coming back.
- What could go wrong
- This is an early phase 2 trial with only 102 participants, so results may not apply to everyone. The drug can cause immune-related side effects, and it may not clear the cancer DNA in all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCOREGIONALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA (LA-HNSCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Canada